Tiagabine for social anxiety disorder.
Tiagabine, a selective gamma-aminobutyric acid (GABA) reuptake inhibitor was evaluated for the treatment of patients with social anxiety disorder (SAD). Adults with SAD received open-label tiagabine 4-16 mg per day for 12 weeks. Intent-to-treat data are available for 54 patients with improvement demonstrated in Liebowitz Social Anxiety Scale, Clinician Global Impression-Severity (CGI-S) and -Improvement (CGI-I), Social Phobia Inventory, and Sheehan Disability Scale scores. In all, 40.7% (22/54) of the intent to treat sample and 63.0% (17/27) of the completer sample were considered CGI responders (CGI-I score of one or two). Tiagabine was generally well tolerated. Results of this pilot study suggest that tiagabine may be an option for the treatment of patients with SAD. Larger, controlled studies are required to fully elucidate the potential of tiagabine for the treatment of SAD.
Dunlop
Boadie W
BW
Department of Psychiatry & Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia 30329, USA. bdunlop@emory.edu
Papp
Laszlo
L
Garlow
Steven J
SJ
Weiss
Paul S
PS
Knight
Bettina T
BT
Ninan
Philip T
PT
D000293:Adolescent; D000328:Adult; D000368:Aged; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005006:Ethnicity; D005260:Female; D018682:GABA Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009557:Nipecotic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D010865:Pilot Projects; D011569:Psychiatric Status Rating Scales; D055502:Secondary Prevention; D012920:Social Behavior Disorders / Q000188:drug therapy* / Q000523:psychology; D000078308:Tiagabine
D018682:GABA Agents; D009557:Nipecotic Acids; D000078308:Tiagabine